On June 28th MEL-PLEX Project Coordinator Prof Markus Rehm received the “Ireland’s Champions of EU Research” recognition awarded by Enterprise Ireland on a special ceremony hosted at the Royal Hospital Kilmainham in Dublin.
The consortium partner OncoMark received a Special Award for its high success in EU funded projects.
More information can be found here.
Regulators in the United States and Europe have approved Amgen’s talimogene laherparepvec, a genetically modified live oncolytic herpesvirus therapy that replicates inside cancer cells and causes them to rupture and die. More information here.